Selective MT2 melatonin receptor antagonist blocks melatonin-induced antinociception in rats

被引:76
|
作者
Yu, CX
Zhu, CB
Xu, SF
Cao, XD
Wu, GC [1 ]
机构
[1] Shanghai Med Univ, Dept Neurobiol, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China
[2] Fujian Med Univ, Dept Pharmacol, Fuzhou 350004, Peoples R China
关键词
melatonin; luzindole; prazosin; melatonin receptor subtype; antinociception; rat;
D O I
10.1016/S0304-3940(00)00883-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The present study was undertaken to assess the effects of intracerebroventricular (i.c.v.) luzindole (a selective MT2 melatonin receptor antagonist) and prazosin (a selective MT3 melatonin receptor antagonist) on melatonin-induced antinociception, so as to clarify which of melatonin receptor subtypes within the central nervous system (CNS) was mediating antinociception. The pain threshold of rats was measured by the hot water (50 degrees C) tail-flick test. It was found that intraperitoneal (i.p.) melatonin (30, 60, 120 mg/kg) resulted in a dose-dependent antinociception. Luzindole (50, 100 mu g) administered intracerebroventricularly antagonized significantly the antinociceptive effect induced by i.p. melatonin (120 mg/kg), whereas prazosin (50 mu g) did not. Neither luzindole (100 mu g, i.c.v.) nor prazosin (50 mu g, i.c.v.) affected the nociceptive threshold when given alone. The results suggest that melatonin-induced antinociception is mediated through the MT2 melatonin receptor subtype within the CNS. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 50 条
  • [21] Pharmacological Characterization of a Highly Selective and Potent Partial Agonist of the MT2 Melatonin Receptor
    Sakurai, Taku
    Koike, Tatsuki
    Nakayama, Masaharu
    PHARMACOLOGY, 2014, 93 (5-6) : 244 - 252
  • [22] Melatonin receptor subtype MT2 (Mel 1b) and not mt1 (Mel 1a) is associated with melatonin-induced enhancement of cell-mediated and humoral immunity
    Drazen, DL
    Nelson, RJ
    NEUROENDOCRINOLOGY, 2001, 74 (03) : 178 - 184
  • [23] Novel Melatonin MT2 Receptor Ligands in Neuropathic Pain
    Gobbi, Gabriella
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S40 - S40
  • [24] Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors
    Renzi, Anastasia
    Glaser, Shannon
    DeMorrow, Sharon
    Mancinelli, Romina
    Meng, Fanyin
    Franchitto, Antonio
    Venter, Julie
    White, Mellanie
    Francis, Heather
    Han, Yuyan
    Alvaro, Domenico
    Gaudio, Eugenio
    Carpino, Guido
    Ueno, Yoshiyuki
    Onori, Paolo
    Alpini, Gianfranco
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2011, 301 (04): : G634 - G643
  • [25] Human amniotic epithelial cells express melatonin receptor MT1, but not melatonin receptor MT2: a new perspective to neuroprotection
    Kaneko, Yuji
    Hayashi, Takuro
    Yu, SeongJin
    Tajiri, Naoki
    Bae, Eunkyung C.
    Solomita, Marianna A.
    Chheda, Sonia H.
    Weinbren, Nathan L.
    Parolini, Ornella
    Borlongan, Cesar V.
    JOURNAL OF PINEAL RESEARCH, 2011, 50 (03) : 272 - 280
  • [26] The melatonin receptor subtype MT2 is present in the human cardiovascular system
    Ekmekcioglu, C
    Thalhammer, T
    Humpeler, S
    Mehrabi, MR
    Glogar, HD
    Hölzenbein, T
    Markovic, O
    Leibetseder, VJ
    Strauss-Blasche, G
    Marktl, W
    JOURNAL OF PINEAL RESEARCH, 2003, 35 (01) : 40 - 44
  • [27] Recent advances in the development of melatonin MT1 and MT2 receptor agonists
    Mor, Marco
    Rivara, Silvia
    Pala, Daniele
    Bedini, Annalida
    Spadoni, Gilberto
    Tarzia, Giorgio
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (08) : 1059 - 1077
  • [28] The end of a myth: cloning and characterization of the ovine melatonin MT2 receptor
    Coge, F.
    Guenin, S. P.
    Fery, I.
    Migaud, M.
    Devavry, S.
    Slugocki, C.
    Legros, C.
    Ouvry, C.
    Cohen, W.
    Renault, N.
    Nosjean, O.
    Malpaux, B.
    Delagrange, P.
    Boutin, J. A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (05) : 1248 - 1262
  • [29] Melatonin MT1 and MT2 receptor expression in Parkinson's disease
    Adi, Nikhil
    Mash, Deborah C.
    Ali, Yousuf
    Singer, Carlos
    Shehadeh, Lina
    Papapetropoulos, Spyridon
    MEDICAL SCIENCE MONITOR, 2010, 16 (02): : BR61 - BR67
  • [30] Involvement of melatonin MT2 receptor mutants in type 2 diabetes development
    Karamitri, Angeliki
    Vincens, Monique
    Chen, Min
    Jockers, Ralf
    M S-MEDECINE SCIENCES, 2013, 29 (8-9): : 778 - 784